• EN
  • FR

abionyx linkedin 1ff75abionyx twitter b3bc9

logo abionyx new21

  • Home
  • About
    • About
    • Abionyx
    • Management
    • Board of Directors
    • Specialized Committees
      • - Audit Committee
      • - Remuneration Committee
    • Scientific Advisory Board
  • Our Assets
    • Our Assets
    • CER 001
    • CER 002
    • CER 209
  • Indications
    • LCAT
    • Sepsis
    • COVID
  • Media
    • Media
    • Press releases
    • ABIONYX in the media
  • Investors
    • Investors
    • Regulated information
    • Shareholder meeting
    • Analyst Research
    • Abionyx on stock market
    • Investor Contacts
    • Financial Calendar
  • Slide
  • Slide
  • Investors
  • Regulated information
  • Shareholder meeting
  • Analyst Research
  • Abionyx on stock market
  • Investor Contacts
  • Financial Calendar

Analyst Research

Midcap Research

05/10/2022 Inclusion of Patients in Racers Study Completed, Results Expected by Late-Autumn acrobat bleu
30/09/2022 Iris Pharma Synergies Exceeding Expectations acrobat bleu
04/07/2022 Scaling Up acrobat bleu
02/12/21 Capital increase of €4.2 million at €3.6 per share (in French) acrobat bleu
18/11/21 Structuring acquisition in the optha., a great opportunity to accelerate (in French) acrobat bleu
15/11/21 Publication in the LCAT indication (in French) acrobat bleu
12/10/21 Merger underway with Iris Pharma in ophthalmology (in French) acrobat bleu
  • Contact
  • Legal notice
  • Processing of personal data
  • Privacy policy
  • General purchase conditions
  • General terms and conditions for procurement of services
© 2023 Abionyx : A new generation biotech company
Back to top